Transactions
7
Insider / Xilio Therapeutics, Inc.
GILEAD SCIENCES, INC.
Insider at Xilio Therapeutics, Inc.
- Company
- Xilio Therapeutics, Inc.
- First filing on record
- October 3, 2025
- Latest trade on record
- May 26, 2026
- SEC filings
- EDGAR ↗
GILEAD SCIENCES, INC., Insider at Xilio Therapeutics, Inc., has disclosed 7 transactions in ASMB, XLO since October 3, 2025: 1 purchase (4 open-market buys) and 0 sales, worth about $24.5M at the reported prices. The latest was filed May 27, 2026, 1 day after the trade; 5 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
4
Sales
0
Avg. disclosure lag
26.1d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months GILEAD SCIENCES, INC. reported 4 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
2 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| P | Open-market purchase | 4 | 8,330,840 | $2.0M |
| X | Exercise of an in-the-money option | 2 | 26,670,000 | $10.0M |
| A | Grant or award | 1 | 471,698 | $12.5M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
| 2025 | 5 | 1 · $0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ASMB | Other A | May 26, 2026 | May 27, 2026 | 1d | 471,698 | $27 | $12.5M | Form 4 ↗ | ||
| XLO | Option / conversion P | February 13, 2026 | February 17, 2026 | 4d | 3,739,000 | $1 | $2.0M | derivative | Form 4 ↗ | |
| XLO | Option / conversion X | November 26, 2025 | December 1, 2025 | 5d | 13,335,000 | — | — | latederivative | Form 4 ↗ | |
| XLO | Option / conversion X | November 26, 2025 | December 1, 2025 | 5d | 13,335,000 | $1 | $10.0M | latederivative | Form 4 ↗ | |
| ASMB | Option / conversion P | August 8, 2025 | October 3, 2025 | 56d | 1,147,960 | — | — | latederivative | Form 4 ↗ | |
| ASMB | Option / conversion P | August 8, 2025 | October 3, 2025 | 56d | 1,147,960 | — | — | latederivative | Form 4 ↗ | |
| ASMB | Buy P | August 8, 2025 | October 3, 2025 | 56d | 2,295,920 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 27, 2026 | Form 4 | 0001123292-26-000751 | 1 | published | EDGAR ↗ |
| February 17, 2026 | Form 4 | 0001123292-26-000187 | 1 | published | EDGAR ↗ |
| December 1, 2025 | Form 4 | 0001123292-25-000675 | 2 | published | EDGAR ↗ |
| October 3, 2025 | Form 4 | 0001123292-25-000510 | 3 | published | EDGAR ↗ |
Other insiders at Xilio Therapeutics, Inc.
- Frankenfield Christopher James Chief Financial Officer 21 rows
- Russo Rene PRESIDENT AND CEO 20 rows
- Luptakova Katarina CHIEF MEDICAL OFFICER 14 rows
- Brennan Kevin M. SVP, FINANCE AND ACCOUNTING 11 rows
- Bonstein Sara Chief Financial Officer 10 rows
- Bjorkquist Jeanette M PFO and PAO 5 rows
- White Nicole S Chief Manufacturing Officer 4 rows
- Delaney William E IV Chief Scientific Officer 2 rows
- Gaggar Anuj Chief Medical Officer 2 rows
- Okazaki Jason A CEO and President 2 rows
Everyone on file, with contracts and lobbying under the company's name: Xilio Therapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 7 | October 3, 2025 | May 27, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.